This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Breast cancer in the male

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Male breast cancer (MBC) accounts comprise about 1% of all breast cancers, world-wide. (1)

  • in UK it is the 26th most common cancer and accounts for less than 1% of male cancer cases (2)

Although the disease remains rare, anecdotal evidence suggests that the rate of male breast cancer is on the rise (3).

  • in UK
    • there were 48,788 new cases of breast cancer out of which less than 1% (371 cases) were males when compared to 48,417 women (female:male ratio of around 131:1) (2)
    • incidence of MBC is strongly related to age - between the years 2007-2009, around 65% of patients with MBC were aged 65 years and over
    • in Britain MBC incidence rates have changed very little since the late 1970s (2)
  • in the USA the current incidence is 0.86-1.08 per 100 000 men and this figure has been on the increase alongside that of women (3)
  • among men with Klinefelter's syndrome, the incidence is comparable to that of women
  • in a South Korean study the 5-year survival rate was 73.7% (4)
    • poor prognostic factors noted were age > 65 years, > 2 comorbidities, no surgical intervention, and no tamoxifen use (4)


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.